Roche, C4 Team Up to Develop Targeted Protein Degradation Treatments

C4 Therapeutics will partner with Swiss drug giant Roche to develop novel treatments in the field of targeted protein degradation.

The agreement — worth up to $750 million — will use C4’s Degronimid technology. C4 will receive an undisclosed upfront payment and be responsible for the initial development of TPD therapeutics that utilize Degronimid technology for a specific set of target proteins.

Roche will have the option to pursue further clinical development and commercialization following the completion of the preclinical development phase.